In vitro antibacterial activity and beta-lactamase stability of the new carbapenem SM-7338

Yoshihiro Sumita, M. Inoue, S. Mitsuhashi

Research output: Contribution to journalArticle

101 Citations (Scopus)

Abstract

The in vitro activity of the new carbapenem SM-7338 was tested in comparison with imipenem, ceftazidime, cefotaxime, flomoxef, cefuzonam and cefmetazole against 2850 clinical bacterial isolates. SM-7338 showed good activity against a broad spectrum of grampositive and gram-negative bacteria. SM-7338 was very active against gram-negative bacteria, inhibiting all Enterobacteriaceae, except 25 % of Serratia marcescens isolates, at a concentration of 0.78 mg/l. SM-7338 inhibited the majority of Pseudomonas spp. at concentrations of ≤ 3.13 mg/l, its activity being twofold higher than that of imipenem. However, the activity of SM-7338 against gram-positive cocci was about one-fourth that of imipenem. Against anaerobes, SM-7338 also had the best activity of the β-lactams tested. The compound was inactive against methicillin-resistant staphylococci, Enterococcus faecium, Xanthomonas maltophilia and Flavobacterium spp., as were the other β-lactams. SM-7338 was quite stable in the presence of various types of β-lactamase, but was hydrolyzed by Xanthomonas maltophilia β-lactamase, as was imipenem. This high degree of stability was responsible for the potent activity of SM-7388 against β-lactamase-producing species such as Enterobacter cloacae, Citrobacter freundii and Proteus vulgaris. SM-7338 also showed bactericidal activity against clinical isolates at the MIC or at concentrations slightly above the MIC.

Original languageEnglish
Pages (from-to)908-916
Number of pages9
JournalEuropean Journal of Clinical Microbiology & Infectious Diseases
Volume8
Issue number10
DOIs
Publication statusPublished - Oct 1 1989
Externally publishedYes

Fingerprint

meropenem
Carbapenems
beta-Lactamases
Imipenem
Stenotrophomonas maltophilia
Lactams
Gram-Negative Bacteria
Cefmetazole
Citrobacter freundii
Proteus vulgaris
Flavobacterium
Enterobacter cloacae
Gram-Positive Cocci
Enterococcus faecium
Serratia marcescens
Methicillin Resistance
Ceftazidime
Cefotaxime
In Vitro Techniques
Enterobacteriaceae

ASJC Scopus subject areas

  • Microbiology (medical)
  • Immunology

Cite this

In vitro antibacterial activity and beta-lactamase stability of the new carbapenem SM-7338. / Sumita, Yoshihiro; Inoue, M.; Mitsuhashi, S.

In: European Journal of Clinical Microbiology & Infectious Diseases, Vol. 8, No. 10, 01.10.1989, p. 908-916.

Research output: Contribution to journalArticle

@article{bc00502d2866409e9478bb91c4108d8b,
title = "In vitro antibacterial activity and beta-lactamase stability of the new carbapenem SM-7338",
abstract = "The in vitro activity of the new carbapenem SM-7338 was tested in comparison with imipenem, ceftazidime, cefotaxime, flomoxef, cefuzonam and cefmetazole against 2850 clinical bacterial isolates. SM-7338 showed good activity against a broad spectrum of grampositive and gram-negative bacteria. SM-7338 was very active against gram-negative bacteria, inhibiting all Enterobacteriaceae, except 25 {\%} of Serratia marcescens isolates, at a concentration of 0.78 mg/l. SM-7338 inhibited the majority of Pseudomonas spp. at concentrations of ≤ 3.13 mg/l, its activity being twofold higher than that of imipenem. However, the activity of SM-7338 against gram-positive cocci was about one-fourth that of imipenem. Against anaerobes, SM-7338 also had the best activity of the β-lactams tested. The compound was inactive against methicillin-resistant staphylococci, Enterococcus faecium, Xanthomonas maltophilia and Flavobacterium spp., as were the other β-lactams. SM-7338 was quite stable in the presence of various types of β-lactamase, but was hydrolyzed by Xanthomonas maltophilia β-lactamase, as was imipenem. This high degree of stability was responsible for the potent activity of SM-7388 against β-lactamase-producing species such as Enterobacter cloacae, Citrobacter freundii and Proteus vulgaris. SM-7338 also showed bactericidal activity against clinical isolates at the MIC or at concentrations slightly above the MIC.",
author = "Yoshihiro Sumita and M. Inoue and S. Mitsuhashi",
year = "1989",
month = "10",
day = "1",
doi = "10.1007/BF01963782",
language = "English",
volume = "8",
pages = "908--916",
journal = "European Journal of Clinical Microbiology and Infectious Diseases",
issn = "0934-9723",
publisher = "Springer Verlag",
number = "10",

}

TY - JOUR

T1 - In vitro antibacterial activity and beta-lactamase stability of the new carbapenem SM-7338

AU - Sumita, Yoshihiro

AU - Inoue, M.

AU - Mitsuhashi, S.

PY - 1989/10/1

Y1 - 1989/10/1

N2 - The in vitro activity of the new carbapenem SM-7338 was tested in comparison with imipenem, ceftazidime, cefotaxime, flomoxef, cefuzonam and cefmetazole against 2850 clinical bacterial isolates. SM-7338 showed good activity against a broad spectrum of grampositive and gram-negative bacteria. SM-7338 was very active against gram-negative bacteria, inhibiting all Enterobacteriaceae, except 25 % of Serratia marcescens isolates, at a concentration of 0.78 mg/l. SM-7338 inhibited the majority of Pseudomonas spp. at concentrations of ≤ 3.13 mg/l, its activity being twofold higher than that of imipenem. However, the activity of SM-7338 against gram-positive cocci was about one-fourth that of imipenem. Against anaerobes, SM-7338 also had the best activity of the β-lactams tested. The compound was inactive against methicillin-resistant staphylococci, Enterococcus faecium, Xanthomonas maltophilia and Flavobacterium spp., as were the other β-lactams. SM-7338 was quite stable in the presence of various types of β-lactamase, but was hydrolyzed by Xanthomonas maltophilia β-lactamase, as was imipenem. This high degree of stability was responsible for the potent activity of SM-7388 against β-lactamase-producing species such as Enterobacter cloacae, Citrobacter freundii and Proteus vulgaris. SM-7338 also showed bactericidal activity against clinical isolates at the MIC or at concentrations slightly above the MIC.

AB - The in vitro activity of the new carbapenem SM-7338 was tested in comparison with imipenem, ceftazidime, cefotaxime, flomoxef, cefuzonam and cefmetazole against 2850 clinical bacterial isolates. SM-7338 showed good activity against a broad spectrum of grampositive and gram-negative bacteria. SM-7338 was very active against gram-negative bacteria, inhibiting all Enterobacteriaceae, except 25 % of Serratia marcescens isolates, at a concentration of 0.78 mg/l. SM-7338 inhibited the majority of Pseudomonas spp. at concentrations of ≤ 3.13 mg/l, its activity being twofold higher than that of imipenem. However, the activity of SM-7338 against gram-positive cocci was about one-fourth that of imipenem. Against anaerobes, SM-7338 also had the best activity of the β-lactams tested. The compound was inactive against methicillin-resistant staphylococci, Enterococcus faecium, Xanthomonas maltophilia and Flavobacterium spp., as were the other β-lactams. SM-7338 was quite stable in the presence of various types of β-lactamase, but was hydrolyzed by Xanthomonas maltophilia β-lactamase, as was imipenem. This high degree of stability was responsible for the potent activity of SM-7388 against β-lactamase-producing species such as Enterobacter cloacae, Citrobacter freundii and Proteus vulgaris. SM-7338 also showed bactericidal activity against clinical isolates at the MIC or at concentrations slightly above the MIC.

UR - http://www.scopus.com/inward/record.url?scp=0024326210&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024326210&partnerID=8YFLogxK

U2 - 10.1007/BF01963782

DO - 10.1007/BF01963782

M3 - Article

C2 - 2512140

AN - SCOPUS:0024326210

VL - 8

SP - 908

EP - 916

JO - European Journal of Clinical Microbiology and Infectious Diseases

JF - European Journal of Clinical Microbiology and Infectious Diseases

SN - 0934-9723

IS - 10

ER -